Liraglutide Case Study

The amount of obese and overweight individuals is increasing every year in the United States. With 33.9% of American adults obese, and 34.4% overweight, but not obese, more and more people are looking for any alternative to lose weight (Anonymous 2011). If someone told you that they knew of a weight loss pill that actually works, would you consider it?

As per Healthy People 2020 most Americans do not consume healthy diets and are not physically active at levels needed to maintain proper health. As a result of these behaviors the nation has experienced a dramatic increase in obesity in the U.S with 1 in 3 adults (34.0%) and 1 and 6 children and adolescents (16.2%) are obese. In addition to grave health consequences of being overweight and obese. It significantly raises medical cost and causes a great burden on the U.S medical care delivery system ("Healthy People 2020," 2014, p. 1).

All patients regardless of healthy BMI or not should have their BMI check by a healthcare worker at least yearly. Patients that are noted to have one co morbidity and a BMI of 25 should be counseled on weight loss. Patients that are noted to be obese have a suggested weight loss goal of anywhere from 3% to 10%. Obesity is a lifestyle disease so it would only be right to have the next point beginning at changing your diet, and physical activity while still counseled by your healthcare worker. When dieting an individual’s diet should be tailored to their co morbidities if any present. Patient that need to be counseled will need to be advised on how to reduce their caloric intake while gradually starting toincreasetheirworkouts and physical activity. A caloric restriction of 1800 kcal for men and 1500 kcal a day for women is usually recommended. Some patients may also benefit from different workout programs like group sessions or one to one sessions with a personal trainer. If those intervention fail and the patient has a BMI of 40 or more or a BMI of 35 or more with one or more comorbidities some form of bariatric surgery may be suggested. There are not many pharmaceutical treatments available for weight loss management. Many of these drugs on the market are known to have severe side effects such as cardiac

Adult overweight and obesity have become a worldwide issue that has very dangerous consequences on health. World Health Organization defines obesity as the “epidemic of the 21st Century”. WHO reports show that 1.9 billion people with 18 years age and older are overweight, and 600 million of them are obese. In the United States, obesity is a serious problem today that results from overconsumption of high-fat food and sugary food with lack of exercise. The Centers for Diseases Control and Prevention reports show that the obesity rates are above 20 percent in all states. Overweight and obesity have become a major public health issue because of their high rates of mortality and morbidity. People who are considered overweight or obese are at increased

Obesity is one of the most rapidly growing health epidemics in the United States and affects more than 60 million people. Despite recent efforts to understand and treat obesity, there has been little success in reversing the rising trend. There is convincing evidence that obesity is directly related to many health risks. As a matter of fact, morbidly obese people are at a high risk for weight related illnesses, such as high blood pressure, type 2 diabetes, high cholesterol, and heart disease. However, research confirms that long-term weight loss success can help to significantly reduce these weight related health risks (Brethauer).

Obesity, the condition of being severely overweight, is a serious issue in the United States that is gradually beginning to affect more and more citizens. In recent years, the number of Americans suffering from this chronic disease has significantly increased. Researchers have found that nearly one third of the U.S. population is considered overweight and, on average, three hundred thousand individuals die yearly as a result of obesity (Hollands et al. 2). When one participates in little to no physical activity and their diet consists mostly of high fat foods, chances are they will gain weight. If someone becomes obese, they may develop serious health related issues that, in some cases,

Obesity rates in the United States are alarming, with more than one-third of U.S. adults and 17% of children qualifying as obese with a Body Mass Index greater than 30.0 (Centers for Disease Control (CDC), 2015). Even more frightening is the growth rate of this crippling health epidemic; between 1980 and 2014, obesity has doubled for adults and tripled for children (CDC, 2015). The physical consequences of rising obesity rates in our country include an abundance of physical ailments including type-2 diabetes, cardiovascular disease, sleep apnea, arthritis, elevated cholesterol, and even some cancers. Additionally, obesity-related health care costs to our country are estimated at $147 billion annually, plus the costs of productivity lost at

It was merely a decade ago that the obesity epidemic was thought to only be a minor problem and had only alarmed a small number of endocrinologists interested by the size of the situation (James, 2008). However today, the problem of obesity is vast with more awareness of its presence by doctors and individuals alike. In fact, the Center for Disease Control and Prevention states, “More than one-third (34.9% or 78.6 million) of U.S. adults are obese (CDC, 2014)”. These numbers are outrageous and eye opening, leaving millions looking for a solution to this troubling epidemic. Obesity is not simply a cosmetic flaw as some might think, but is actually a very dangerous state of being for any individual to sustain long-term. Mentioned further in

Liraglutide is novel approach in combating T2DM. It works as a DPP-4 inhibitor via catalyzing GLP-1 receptor affinity, which will in-turn inhibit gastrointestinal motility, while increasing satiety and decreasing energy intake. The exact mechanisms on how this occurs continues to be researched. There also appears to be different results in regards to how Liraglutide is administered. When is administered orally, GLP-1 is shown to inhibit meal-induced gastric acid secretion while slowing down gastric emptying rate. Intravenous infusion of GLP-1 was shown to increase satiety, decrease the sensation of hunger, which again, reduces overall intake (Flint et al.1998)(Flint et al.2001). Like all new drugs and therapies that are introduced into the market, it’s difficult to gauge the long term effects of drugs in a short period of time. With Liraglutide being fairly new inot the market for treating obesity, patience and research is vital for understanding the mechanisms of its function as well as the dysfunction it could promote in patients. Liraglutide appears to be promising in combating obesity, and with its 97% homology to that of GLP-1, there might be evidence in favor of it in the near future

Obesity is one of the most common problems faced by people today. Since thirty-four million Americans are estimated to be obese, one out of every three Americans must live with this disorder. Obesity is defined as a body weight consisting of 20% or more above the standard ideal weight (http://www-med.stanford.edu/school/DGIM/Teaching/Modules/obesity.html#RTFToC12). In order to reduce obesity, most invest in diet and exercise programs. Recently, liquid diets have been positively modified, thus rising in popularity since their fall out during the late 1970’s. Out of the twenty million dieters, about one billion dollars will be spent this year on either medically sponsored liquid diets or over-the-counter liquid diet

There are only several other weight-loss options in the market competing with Metabical. The first is prescription drugs. These are prescribed for use only by obese and severely obese individuals. This meant that only individuals with BMI of over 30 who were prescribed weight-loss drugs were using appetite suppressants and fat-absorbing blockers. They had serious side effects associated as well, which meant only a doctor could approve them. But these prescription-drug options did not account for the overweight segment with

Liraglutide is a new drug for weight management presently in clinical trial. Explain the proposed mechanism of the drug and briefly report the outcome of the clinical trials.

term paper examples. Metabical: Positioning and Communications Strategy for a New Weight Loss Drug Executive Summary Excess weight is considered a significant...

Numerous studies have been done surrounding the effects of PPA on weight loss. Most studies show that using the appetite suppressant, PPA along with diet and exercise will promote weight loss. PPA has been shown to be extremely effective in helping people eat less and achieve the ultimate goal of losing weight. In 1975, a study with 70 volunteers concluded “the subjects lost three times as much weight while taking PPA than while taking the placebo (Lasagna, p.393).” Another

Statistics show that a large fraction of the population is suffering from obesity as a consequence of poor eating habits. A good percentage of that number is also actively seeking to lose weight through less exhaustive and straining means such as exercise and dieting. The easy way out for them is through weight loss supplements whose demand has created booming business for its producers.